A photo of Yi Zheng.

Yi Zheng, PhD

Director, Experimental Hematology and Cancer Biology

Katherine Stewart Waters Endowed Chair

Co-Director, Cancer and Blood Diseases Institute

Professor, UC Department of Pediatrics

Phone 513-636-0595

Fax 513-636-3768

Email yi.zheng@cchmc.org

Research Interests

Using transgenic and gene targeted mouse models to study the physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis, neurogenesis, lung cancer development and small intestinal stem cell regulations; mechanism based, rational design of small molecule inhibitors targeting Rho GTPase signaling modules and pathologic functions in cancer and blood diseases; mouse model studies of mTor signaling function in hematopoietic stem cells and small intestinal stem cells.

Visit the Zheng Lab.

BS: Tsinghua University, Beijing, China, 1986.

MS: Cornell University, Ithaca, NY 1988.

PhD: Cornell University, Ithaca, NY, 1991.

Postdoctoral Fellow: Cornell University, Ithaca, NY, 1995.

Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, Wortman M, Zheng Y. Small molecule inhibitors targeting G-protein coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60.

Guo F, Zhang S, Grogg M, Cancelas JA, Varney ME, Starczynowski DT, Du W, Yang JQ, Liu W, Zhu W, Thomas G, Kozma S, Pang Q, Zheng Y. Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis . Haematologica. 2013 Sep;98(9):1353-8.

Guo F, Li J, Du W, Zhang S, O'Connor M, Thomas G, Kozma S, Zingarelli B, Pang Q, Zheng Y. mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells. Leukemia. 2013 Oct;27(10):2040-6.

Guo F, Li J, Zhang S, Du W, Amarachintha S, Sipple J, Phelan J, Grimes HL, Zheng Y,* Pang Q.* mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expressionLeukemia. 2013 Jul 15. [Epub ahead of print] *Co-corresponding authors.

Florian MC, Nattamai KJ, Dörr K, Marka G, Ueberle B, Vas V, Eckl C, Andrä I, Schiemann M, Oostendorp RA, Scharffetter-Kochanek K, Kestler HA, Zheng Y, Geiger H. A canonical to non-canonical Wnt signalling switch in hematopoietic stem cell ageing. Nature. 503(7476):392-6.

Melendez J, Liu M, Sampson L, Akunuru S, Han X, Vallance J, Witte D, Shroyer N, Zheng Y. Cdc42 coordinates cell polarity, migration, proliferation and differentiation of the small intestinal epithelium. Gastroenterology. 2013 Oct;145(4):808-19.

Zhou X, Florian MC, Arumugam P, Chen X, Cancelas JA, Lang R, Malik P, Geiger H, Zheng Y. RhoA GTPase Controls Mitosis and Programmed Necrosis of Hematopoietic Progenitors. J Exp Med. 2013 Oct 21;210(11):2371-85.

Katayama K, Imai F, Campbell K, Lang RA, Zheng Y, Yoshida Y. RhoA and Cdc42 are required in pre-migratory progenitors of the medial ganglionic eminence ventricular zone for proper cortical interneuron migration. Development. 2013 Aug;140(15):3139-45.

Zhou X, Zheng Y. Cell type specific signaling role of RhoA GTPase: lessons from mouse gene targeting. J Biol Chem. 288(51):36179-88.

Geiger H, Zheng Y. Cdc42 and aging of hematopoietic stem cells. Curr Opin Hematol. 2013 Jul;20(4):295-300.

Rac GTPase specific small molecule inhibitors. PI: Yi Zheng. National Cancer Institute. NIH - R01 CA141341. 01/01/2000 - 01/31/2014

Targeting Cdc42 in leukemia stem cells. PI: Yi Zheng, co-PI: James Mulloy. National Cancer Institute - 1R01CA150547-01. 04/01/2010 – 03/31/2015

Cincinnati Center of Excellence in Molecular Hematology. PI: Yi Zheng. NIDDK - NIH P30 DK090971. 09/30/2010 – 06/30/2015

Lineage Determination and Tissue Homeostasis in the aged Hematopoietic System. PI: Yi Zheng; co-PI: Hartmut Geiger. NIA - NIH R01AG040118. 08/01/2011 – 07/31/2016

PHARMACOLOGICAL REJUVENATION OF AGED HEMATOPOIETIC STEM CELLS. PI: Hartmut Geiger; co-PI: Yi Zheng. NIH - NIH R43 AG042986. 08/01/2012 – 07/31/2014

Targeting Leukemia-associated Rho guanine nucleotide exchange factor LARG in AML. PI: Yi Zheng; co-PI: James Mulloy. Alex’s Lemonade Stand Foundation. 07/01/2013 – 06/30/2015